Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LINC02308 is a human long intergenic non-coding RNA recognized for its significant overexpression in glioma tissue and association with poor patient prognosis. It functions primarily by binding to specific microRNAs such as miR-30e-3p, thereby modulating their activity and affecting downstream signaling pathways like AKT/mTOR. Through these mechanisms, LINC02308 can promote tumor cell proliferation, inhibit apoptosis, and play an oncogenic role in cancer biology. While not a classical drug target, it receives growing attention as a potential biomarker and mediator in the regulation of gene expression and disease pathways.
For interacting molecules: Acts by sequestering miR-30e-3p, upregulating TM4SF1, subsequently activating the AKT/mTOR pathway
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 2308 (LINC02308).